Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

VyrarX vs Wisp

VyrarX
Graded #145

Higher grade

vs+4.199999999999989
Wisp
Graded #243

Lower grade

The verdict

VyrarX takes it — 68.6/100 to 64.4/100.

VyrarX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. VyrarX is a LegitScript-certified telehealth platform offering compounded semaglutide (from $179/month) and compounded tirzepatide (from $329/month) via weekly injection, prescribed by licensed US physicians.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueVyrarX +11
61
50
Dose & formulationWisp +12
64
76
Clinical oversightVyrarX +2
84
82
Labs & monitoringVyrarX +19
72
53
FulfillmentVyrarX +5
71
66
Contract termsEven
55
55
VyrarX · left barWisp · right bar

The numbers

MetricVyrarXWisp
WeighScore68.6/10064.4/100
GradeCC
Scorecard rank#145#243
Semaglutide$179/mo (starting dose, compounded)$225/mo (compounded oral)
Tirzepatide$329/mo (starting dose, compounded)Not disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
VyrarX

Graded #145 · C

Strengths

  • LegitScript certified with active seal (ID 51177727)
  • Semaglutide starting at $179/month with free shipping included
  • 1:1 direct provider messaging and personalized titration plan in every plan
  • Nutrition coaching included with the weight-loss program
  • Provider review completed within 24 hours; no insurance required

Where it loses points

  • Tirzepatide at $329/month starting is at the high end of the compounded market
  • Compounding pharmacy not named on any public page
  • No physician names or clinical leadership disclosed publicly
  • Only 47 states covered — the 3 excluded states are not named on the site
  • Labs not included in the weight-loss plan
Wisp

Graded #243 · C

Strengths

  • Broad GLP-1 menu — branded injectables (Wegovy, Zepbound, Saxenda) plus a compounded sublingual option
  • LegitScript certified with named board-certified providers (Dr. Shannon Chatham DO, Andrea Sleeth WHNP-BC)
  • Unusually candid about the sublingual option's limits, noting effectiveness in patients may vary

Where it loses points

  • The $99/mo tirzepatide figure is a consultation-and-care subscription, not the medication: Zepbound is filled at a pharmacy of your choice at its own cost, which Wisp does not publish
  • The compounded semaglutide option is sublingual drops, which Wisp itself describes as less effective than injection
  • Brand-name access is a prescription, not a dispensed product, so the drug cost is outside anything quoted here

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard